Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
Matthew J. Matasar,Nancy L. Bartlett,Mazyar Shadman,Lihua E. Budde,Ian W. Flinn,Gareth P. Gregory,Won Seog Kim,Georg Heß,Dima El‐Sharkawi,Catherine Diefenbach,Huang Huang,Iris To,Joana Parreira,Mei Wu,Antonia Kwan,Sarit Assouline
Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody approved in Europe and the United States for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies.
Candice
杳鸢
我是站长才怪
tuanheqi
火星上的菲鹰
Suzy
jyy
sissiarno
HEIKU
VDC
不安青牛
蓝波酱
情怀
完美世界
Serendipity
33
yannic
Tan
cocolu
wen
皖公网安备34019202002308
